Contineum Therapeutics (CTNM) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 41.4% versus a gain of 8.4%. Contineum Therapeutics is the larger company by market cap ($503.4 million vs $480.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | OVID |
|---|---|---|
| Share price | $13.38 | $2.46 |
| Market cap | $503.37M | $480.43M |
| 1-day change | +1.52% | +5.13% |
| YTD return | +15.31% | +50.92% |
| 1-year return | +8.39% | +41.38% |
| 5-year return | — | -31.67% |
| EPS (TTM) | $-1.73 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.79 | $3.11 |
| 52-week low | $8.60 | $1.18 |
| Distance from 52-week high | -24.77% | -20.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.64% | +144.72% |
| Average volume | 520.62K | 1.57M |
| Shares outstanding | 32.96M | 195.30M |
| Employees | 51 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed CTNM by 33.0 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
CTNM vs OVID FAQ
Which is bigger, Contineum Therapeutics or Ovid Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $503.37M compared with $480.43M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, CTNM or OVID?
OVID returned +41.38% over the past 12 months, compared with +8.39% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.